risperidone has been researched along with Cardiovascular Diseases in 15 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Risperidone and paliperidone palmitate are two antipsychotic drugs well tolerated in the management of schizophrenia and other psychiatric conditions." | 7.88 | Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability. ( Tagne Nouemssi, AB, 2018) |
| "Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)." | 7.73 | Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "In March 2004, the UK Committee of Safety of Medicines (CSM) informed clinicians that risperidone and olanzapine should not be used to treat behavioural and psychological symptoms of dementia (BPSD) because of increased risk of strokes with both drugs and increased risk of mortality with olanzapine." | 7.73 | Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued? ( Shah, A, 2006) |
| "Risperidone and paliperidone palmitate are two antipsychotic drugs well tolerated in the management of schizophrenia and other psychiatric conditions." | 3.88 | Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability. ( Tagne Nouemssi, AB, 2018) |
| "Following several years of treatment, risperidone discontinuation is associated with a reversal of the excessive weight gain, mediated by a negative energy balance, and a corresponding improvement in cardiometabolic parameters." | 3.80 | Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. ( Burns, TL; Calarge, CA; Nicol, G; Schlechte, JA, 2014) |
| " The aims of this study were to investigate the antioxidative activity of paraoxonase and assess lipid profile as a cardiovascular risk factor in patients with schizophrenia under long-term clozapine or risperidone treatment." | 3.80 | A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. ( Atanasiu, V; Delia, C; Gaman, L; Gilca, M; Iosif, L; Piriu, G; Stoian, I, 2014) |
| "Data were collected from medical records from January 1992 to December 2003 and included age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation for clozapine-treated patients with schizophrenia or schizoaffective disorder (DSM-IV criteria)." | 3.73 | Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. ( Borba, CP; Cather, C; Copeland, PM; Evins, AE; Freudenreich, O; Goff, DC; Hayden, DL; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "In March 2004, the UK Committee of Safety of Medicines (CSM) informed clinicians that risperidone and olanzapine should not be used to treat behavioural and psychological symptoms of dementia (BPSD) because of increased risk of strokes with both drugs and increased risk of mortality with olanzapine." | 3.73 | Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued? ( Shah, A, 2006) |
| " Generally, the antipsychotics significantly enhanced NRG1/ErbB signaling with increased expression of NRG1 and phosphorylation of ErbB4 and ErbB2 in the brain and myocardium, except that clozapine partly blocked the cardiac NRG1/ErbB2 activation, which could be associated with its more severe cardiac adverse actions." | 1.43 | Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect. ( Cai, H; Dang, R; Guo, Y; Jiang, P; Liang, D; Lv, C; Yang, R, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hsueh, L | 1 |
| Iturralde, E | 1 |
| Slama, NE | 1 |
| Spalding, SR | 1 |
| Sterling, SA | 1 |
| Matera, E | 1 |
| Margari, L | 1 |
| Palmieri, VO | 1 |
| Zagaria, G | 1 |
| Palumbi, R | 1 |
| Margari, F | 1 |
| Tagne Nouemssi, AB | 1 |
| Gopal, S | 1 |
| Hough, D | 1 |
| Karcher, K | 1 |
| Nuamah, I | 1 |
| Palumbo, J | 1 |
| Berlin, JA | 1 |
| Baseman, A | 1 |
| Xu, Y | 1 |
| Kent, J | 1 |
| Calarge, CA | 1 |
| Nicol, G | 1 |
| Schlechte, JA | 1 |
| Burns, TL | 1 |
| Gilca, M | 1 |
| Piriu, G | 1 |
| Gaman, L | 1 |
| Delia, C | 1 |
| Iosif, L | 1 |
| Atanasiu, V | 1 |
| Stoian, I | 1 |
| Pasternak, B | 1 |
| Svanström, H | 1 |
| Ranthe, MF | 1 |
| Melbye, M | 1 |
| Hviid, A | 1 |
| Dang, R | 1 |
| Guo, Y | 1 |
| Cai, H | 1 |
| Yang, R | 1 |
| Liang, D | 1 |
| Lv, C | 1 |
| Jiang, P | 1 |
| Osborn, D | 1 |
| Marston, L | 1 |
| Nazareth, I | 1 |
| King, MB | 1 |
| Petersen, I | 1 |
| Walters, K | 1 |
| Meyer, JM | 1 |
| Davis, VG | 1 |
| McEvoy, JP | 1 |
| Goff, DC | 2 |
| Nasrallah, HA | 1 |
| Davis, SM | 1 |
| Daumit, GL | 1 |
| Hsiao, J | 1 |
| Swartz, MS | 1 |
| Stroup, TS | 1 |
| Lieberman, JA | 1 |
| Clark, D | 1 |
| Skrobot, OA | 1 |
| Adebiyi, I | 1 |
| Susce, MT | 1 |
| de Leon, J | 1 |
| Blakemore, AF | 1 |
| Arranz, MJ | 1 |
| Henderson, DC | 1 |
| Nguyen, DD | 1 |
| Copeland, PM | 1 |
| Hayden, DL | 1 |
| Borba, CP | 1 |
| Louie, PM | 1 |
| Freudenreich, O | 1 |
| Evins, AE | 1 |
| Cather, C | 1 |
| Shah, A | 1 |
| Zarate, CA | 1 |
| Baldessarini, RJ | 1 |
| Siegel, AJ | 1 |
| Nakamura, A | 1 |
| McDonald, J | 1 |
| Muir-Hutchinson, LA | 1 |
| Cherkerzian, T | 1 |
| Tohen, M | 1 |
| Bouchard, RH | 1 |
| Demers, MF | 1 |
| Simoneau, I | 1 |
| Alméras, N | 1 |
| Villeneuve, J | 1 |
| Mottard, JP | 1 |
| Cadrin, C | 1 |
| Lemieux, I | 1 |
| Després, JP | 1 |
1 review available for risperidone and Cardiovascular Diseases
| Article | Year |
|---|---|
Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials.
Topics: Antipsychotic Agents; Cardiovascular Diseases; Databases, Factual; Drug Labeling; Humans; Incidence; | 2013 |
1 trial available for risperidone and Cardiovascular Diseases
| Article | Year |
|---|---|
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Dibenzothiazepines; Female; H | 2008 |
13 other studies available for risperidone and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiometabolic Monitoring and Sociodemographic and Clinical Characteristics of Youths Prescribed Antipsychotic Medications.
Topics: Adolescent; Adult; Antipsychotic Agents; Cardiovascular Diseases; Female; Humans; Lipids; Male; Psyc | 2023 |
Risperidone and Cardiometabolic Risk in Children and Adolescents: Clinical and Instrumental Issues.
Topics: Adolescent; Antipsychotic Agents; Cardiovascular Diseases; Child; Child, Preschool; Female; Follow-U | 2017 |
Risperidone-associated sinus tachycardia potentiated by paliperidone palmitate in a patient with no prior cardiovascular disease: role of risperidone-related autonomic instability.
Topics: Antipsychotic Agents; Autonomic Nervous System; Cardiovascular Diseases; Diagnosis, Differential; Do | 2018 |
Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.
Topics: Adolescent; Cardiovascular Diseases; Child; Female; Follow-Up Studies; Humans; Male; Metabolic Syndr | 2014 |
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Aryldialkylphosphatase; Cardiovascular Diseases; Clozapine; Female; Hum | 2014 |
Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in Denmark.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Disea | 2014 |
Effects of prolonged antipsychotic administration on neuregulin-1/ErbB signaling in rat prefrontal cortex and myocardium: implications for the therapeutic action and cardiac adverse effect.
Topics: Animals; Antipsychotic Agents; Cardiovascular Diseases; Clozapine; Comorbidity; Genetic Predispositi | 2016 |
Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Cohort Studies; Female; | 2017 |
Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients.
Topics: Alleles; Antipsychotic Agents; Apolipoproteins E; Body Mass Index; Cardiovascular Diseases; Diabetes | 2009 |
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
Topics: Adult; Antipsychotic Agents; Black or African American; Cardiovascular Diseases; Cause of Death; Clo | 2005 |
Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cardiovascular | 2006 |
Risperidone in the elderly: a pharmacoepidemiologic study.
Topics: Age Factors; Aged; Aged, 80 and over; Basal Ganglia Diseases; Cardiovascular Diseases; Comorbidity; | 1997 |
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Cardiovascular Diseases; Cross-Sectional | 2001 |